Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8668931 | TAKEDA PHARMS USA | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
Sep, 2023
(6 months ago) | |
US8470368 | TAKEDA PHARMS USA | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
Sep, 2023
(6 months ago) | |
US9060941 | TAKEDA PHARMS USA | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
Sep, 2023
(6 months ago) | |
US7785627 | TAKEDA PHARMS USA | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
Jul, 2026
(2 years from now) | |
US7959946 | TAKEDA PHARMS USA | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
Jul, 2026
(2 years from now) |
Actoplus Met Xr is owned by Takeda Pharms Usa.
Actoplus Met Xr contains Metformin Hydrochloride; Pioglitazone Hydrochloride.
Actoplus Met Xr has a total of 5 drug patents out of which 3 drug patents have expired.
Expired drug patents of Actoplus Met Xr are:
Actoplus Met Xr was authorised for market use on 12 May, 2009.
Actoplus Met Xr is available in tablet, extended release;oral dosage forms.
The generics of Actoplus Met Xr are possible to be released after 31 July, 2026.
Drugs and Companies using METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE ingredient
Market Authorisation Date: 12 May, 2009
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE;ORAL